Skip Navigation LinksHome > July 2014 - Volume 21 - Issue 7 > What if the Women’s Health Initiative had used transdermal e...
Menopause:
doi: 10.1097/GME.0000000000000169
Personal Perspective

What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead?

Simon, James A. MD, CCD, NCMP, IF, FACOG

Collapse Box

Abstract

The author considers hypothetical comparisons between oral conjugated equine estrogens and transdermal estradiol and between oral medroxyprogesterone acetate and oral micronized progesterone for their effects on four primary outcomes of the Women’s Health Initiative (WHI): cardiovascular disease risk, cerebrovascular disease risk, venous thromboembolism risk, and breast cancer risk. Although the discussion in this article focuses on transdermal estradiol delivered through patches, gels, or lotions, it could be broadened to include all forms of nonoral estrogen administration. After a brief review of the WHI and a survey of the relevant literature in which the safety of these various hormone therapies is assessed or compared, the author uses statistical methods to ascertain the attributable risk of venous thromboembolism for transdermal estradiol versus oral hormone therapy and imputes those risks into the WHI primary outcomes.

© 2014 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.